Clinical Trials Logo

Clinical Trial Details — Status: Suspended

Administrative data

NCT number NCT03186456
Other study ID # SCLnow-IMIMH-02
Secondary ID
Status Suspended
Phase Phase 1
First received
Last updated
Start date December 31, 2024
Est. completion date December 31, 2025

Study information

Verified date April 2024
Source Sclnow Biotechnology Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purposes of the study is to determine the safety and efficacy of treating acute ischemic stroke patients with human umbilical cord mesenchymal stem cells (hUC-MSC).


Description:

This is a randomized, double-blind, paralleled study. 40 patients will be separated into two groups, and receive basic treatment (Aspirin Tablet). Patients in experimental group will receive hUC-MSC once a month, total 3 times. After the treatment, investigator will have follow-up visit for 6 months, evaluate the security and efficacy of hUC-MSC.


Recruitment information / eligibility

Status Suspended
Enrollment 40
Est. completion date December 31, 2025
Est. primary completion date June 30, 2025
Accepts healthy volunteers No
Gender All
Age group 40 Years to 75 Years
Eligibility Inclusion Criteria: - Patient within 2 weeks onset of symptoms. - Symptoms and signs of clinically definite acute cerebral infarction patients. - CT/MRI prove the Oxfordshire Community Stroke Project (OCSP) as Total Anterior circulation infarct (TACI), Partial Anterior circulation infarct (PACI), Posterior Anterior circulation infarct (POCI), or obvious neurological deficit lacunar infarction patient. - Signed informed consent after understanding all possible benefits and harm. Exclusion Criteria: - allergic to basic drug - with progressive stroke, transient ischemia attach, cerebral infarction with posterior cerebral hemorrhage, and cerebral arteritis. - tumor, injury, and parasites caused cerebral embolism - rheumatic heart disease, coronary heart disease, and other atrial fibrillation combined heart disease caused cerebral embolism - subject is processing thrombolytic therapy - subject is pregnancy and of childbearing potential or breast feeding - participate in any other clinical trial in last 3 months - bleeding tendency patient; severe bleeding tendency in last 3 month - with gastric duodenal ulcer - participants with severe liver and kidney, hematopoietic, and metabolic diseases; Or with liver and kidney function examination abnormal - participants are intolerance with Aspirin Enteric-coated Tablets, or need other antiplatelet drugs - participants: alcoholism, drug addicted, or other situations may complicated the results - under other therapy that possibly influence MSC security or efficacy - investigator supposes not suitable to participate this clinical trail

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#)
Allogeneic umbilical cord mesenchymal stem cells will transfusion into by forearm intravenous transplantation, 0.5 - 1 *10^6/kg. once a month, total 3 times.
Drug:
Aspirin Tablet
Drug: Aspirin Tablet, 100 mg/d

Locations

Country Name City State
China Inner Mongolia International Mongolian Hospital Hohhot Inner Mongolia

Sponsors (1)

Lead Sponsor Collaborator
Sclnow Biotechnology Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Treatment related-adverse events counting patients will be monitored for any adverse events resulting from the treatment of Human Umbilical Cord Mesenchymal Stem Cells 26 weeks
Secondary Modified Rankin Scale After the first time transplantation, follow-up visit for 26 weeks. Based on Modified Rankin Scale, counting the percentage of different symptom changes to evaluate MSC efficacy:
the percentage of participants run from 0-1, no symptom or no significant disability.
the percentage of participants run from 0-2, no symptom or slight disability.
the percentage of participants decline 2 scales compare to baseline.
the percentage of participants decline 1 scale compares to baseline.
26 weeks
Secondary Barthel activities of daily living (ADL) Index Based on Activity of Daily Living Scale (ADL) to counting the percentage of patients in following condition:
the percentage of patients with score > 75
the decline of Barthel ADL Index range compares to baseline. Evaluate the efficacy of MSCs treatment
26 weeks
Secondary NIH stroke scale (NIHSS) According to NIHSS changes after the treatment, evaluate MSCs efficacy by counting the percentage of patients in following condition:
the percentage of patients with score 0-1;
the percentage of patients with score declined 7 compare to baseline;
the percentage of patients with score declined 50% compare to baseline;
the declined ranges compare to baseline
26 weeks
See also
  Status Clinical Trial Phase
Withdrawn NCT02551003 - Neuroprotective Effect of Autologous Cord Blood Combined With Therapeutic Hypothermia Following Neonatal Encephalopathy Phase 1/Phase 2
Completed NCT03281590 - Stroke and Cerebrovascular Diseases Registry
Recruiting NCT03605381 - MORbidity PRevalence Estimate In StrokE
Completed NCT00684515 - Trial to Assess the Safety of Vorapaxar in Japanese Subjects With Cerebral Infarction (P05005; MK-5348-017) Phase 2
Not yet recruiting NCT04082091 - Screening, Early Referral and Lifestyle Tailored E_prescription for Cardiovascular Prevention
Completed NCT01915368 - Determining Optimal Post-Stroke Exercise (DOSE) N/A
Terminated NCT01684462 - The Efficacy and Safety Study of ALbumin Therapy in Acute Ischemic Stroke Phase 2
Completed NCT00386191 - Safety and Efficacy of Clopidogrel for Cerebral Infarction Treatment Phase 4
Completed NCT00004734 - Vitamin Therapy for Prevention of Stroke Phase 3
Completed NCT02684825 - Detection of Silent Atrial Fibrillation aFter Ischemic StrOke N/A
Completed NCT02248233 - Nimodipine for Treating Acute Massive Cerebral Infarction Phase 4
Completed NCT02963545 - TSK (Tryptophan - Serotonin - Kynurenine) Biomarkers Assessment in Stroke N/A
Completed NCT02511249 - Early Determinants of Multidimensional Outcome at School Age After Neonatal Arterial Ischemic Stroke N/A
Completed NCT02101606 - Penumbral Based Novel Thrombolytic Therapy in Acute Ischemic Stroke Phase 2
Completed NCT00829361 - Stroke Telemedicine for Arizona Rural Residents Trial N/A
Completed NCT01500421 - Safty and Feasibility Study of Therapeutic Cooling in Acute Ischemic Stroke (COOLAID Øresund) Phase 2
Recruiting NCT01003470 - Treating Apoplectic Sequela With Acupuncture: a Randomized Controlled Study Phase 2
Terminated NCT00331890 - ICTUS Study: International Citicoline Trial on Acute Stroke Phase 3
Not yet recruiting NCT04696523 - Effect of Xenon on Brain Injury After Aneurysmal Subarachnoid Hemorrhage Phase 2
Completed NCT03741400 - Virtual Reality Glove for Hand and Arm Rehabilitation After Stroke N/A